Home Featured Page 177

Featured

Latest

Jackie Tileston: Nondual Mysticism, 5-MeO-DMT, and the Trouble with Psychedelic Art

FDA Approves NRx’s Preservative-Free Generic Ketamine, but Its Bid to Ban Rivals’ Products Remains Pending

Weekly Psychedelic Policy Briefing: Oct. 27, 2026

Pharma Moves In: Investors, Developers and Lilly’s Carole Ho at the Psychedelic Healthcare Forum

Mostly Supportive, Somewhat Divided: Stakeholders Respond to FDA’s Psychedelics Docket

GH Research Reports Second Quarter 2022 Financial Results and Provides Business...

PT349 – Brenna Gebauer – Slowing Down, The Ethics of Touch,...

Opinions | The Psychedelic Community Takes Itself Too Seriously

Algernon Pharmaceuticals Announces Private Placement

Issues of Patient Safety and Ethical Violations in Psychedelic Therapy

Psychedelic Bulletin #115 – Mydecine Looks Set to Shutter; MindMed Gains...

PT348 – Steve DeAngelo – Cannabis and Psychedelics: Industry, Consciousness, Justice,...

HAVN Life Announces the close of the first tranche of its...

Bright Minds Biosciences Comments on Recent Trading Activity

EDITOR PICKS

Jackie Tileston: Nondual Mysticism, 5-MeO-DMT, and the Trouble with Psychedelic Art

FDA Approves NRx’s Preservative-Free Generic Ketamine, but Its Bid to Ban...

Weekly Psychedelic Policy Briefing: Oct. 27, 2026

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Jackie Tileston: Nondual Mysticism, 5-MeO-DMT, and the Trouble with Psychedelic Art

FDA Approves NRx’s Preservative-Free Generic Ketamine, but Its Bid to Ban Rivals’ Products Remains Pending

Weekly Psychedelic Policy Briefing: Oct. 27, 2026

Pharma Moves In: Investors, Developers and Lilly’s Carole Ho at the Psychedelic Healthcare Forum

Mostly Supportive, Somewhat Divided: Stakeholders Respond to FDA’s Psychedelics Docket

GH Research Reports Second Quarter 2022 Financial Results and Provides Business...

PT349 – Brenna Gebauer – Slowing Down, The Ethics of Touch,...

Interview | Josh Ismin, Psylo

Opinions | The Psychedelic Community Takes Itself Too Seriously

Algernon Pharmaceuticals Announces Private Placement

Issues of Patient Safety and Ethical Violations in Psychedelic Therapy

Psychedelic Bulletin #115 – Mydecine Looks Set to Shutter; MindMed Gains...

PT348 – Steve DeAngelo – Cannabis and Psychedelics: Industry, Consciousness, Justice,...

HAVN Life Announces the close of the first tranche of its...

Bright Minds Biosciences Comments on Recent Trading Activity

EDITOR PICKS

Jackie Tileston: Nondual Mysticism, 5-MeO-DMT, and the Trouble with Psychedelic Art

FDA Approves NRx’s Preservative-Free Generic Ketamine, but Its Bid to Ban...

Weekly Psychedelic Policy Briefing: Oct. 27, 2026

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY